Aptar Active Material Science has launched its Activ-Film technology with a capsule-based Dry Powder Inhalation (DPI) drug product. The solution leverages Aptar’s technology to help safeguard the drug and support product performance throughout shelf life.
The launch marks Aptar’s first commercialization of Activ-Film technology for use with a dry powder inhalation system, building on past FDA approvals of oral solid dosage drugs, implants, and diagnostic products that incorporate this technology.
Badre Hammond, VP of Commercial Operations and general manager at Aptar Active Material Science, says: “The launch of a capsule-based DPI with our Activ Film technology marks a milestone in Aptar’s mission to drive use of material science to advance drug delivery performance and patient experience.”
High performance throughout shelf life
Activ-Film technology uses the company’s 3-Phase Activ-Polymer platform, which is said to offer various customized and highly engineered materials, deployed in a range of configurations. For this launch, Aptar’s Activ-Film material is integrated into the blister packaging that houses the DPI’s dry-powder capsules.
“In this configuration, a piece of custom-engineered Activ-Film material is sealed in an aluminum blister cavity with a channel connecting it to the drug product,” says Aptar Active Material Science.
The design allows the properties of the Activ-Film material to control the microclimate inside the drug blister cavity without coming into contact with the drug capsule itself.
Aptar’s Activ-Polymer technology is developed to assist pharmaceutical partners in meeting drug-specific long-term and in-use stability requirements while supporting therapeutic performance. The solution aims to maintain stability, mitigate degradation and impurities risk, and reinforce overall drug product integrity.
Recently, Aptar Active Material Science secured a US patent for its N-Sorb technology to reduce nitrosamine impurities associated with packaging pharmaceuticals.
Last month, Aptar Pharma announced a system-level data package for injectable drug delivery systems to aid customers in making “more informed” development decisions. In collaboration with its partners, the data package combines system-level testing and performance data, such as container closure integrity and sealing requirements, for injectable therapies.
Last year, Aptar CSP Technologies opened a medical packaging facility in New Jersey, US. The new site enables the pharma pack provider to expand its service offerings to cGMP-compliant manufacturing.
Source: packaginginsights.com
The restructuring forms part of GSK’s “accelerating growth” strategy that was first announced in July. At the time, GSK CEO Luke Miels explained the pharma was seeking 1.9 billion pounds ($2.5 billion) in annual cost-savings by 2029 to fund the program.
Gilead Sciences and Vir Biotechnology have deepened their ties by inking a second deal, which will see the pair join forces to discover and engineer novel T-cell engager (TCE) therapies for solid tumours. Through this collaboration and licensing agreement, Gilead will hand over $90m upfront and up to $45m in potential near-term preclinical milestones.
AstraZeneca has inked a billion-dollar artificial intelligence (AI)-powered drug discovery partnership and licensing deal with insitro, to identify novel targets and therapies for a range of cardiometabolic diseases.
